Article

COVID-19: BELKIN Laser CEO offers company update

Author(s):

Alex Delaney-Gesing

Daria Lemann-Blumenthal, CEO of BELKIN Laser Ltd, provides an update on how the company's operations have continued to progress amid the coronavirus pandemic.

 

See more coronavirus coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
Related Content
iSTAR Medical announces positive 5-year data from STAR-GLOBAL trial for MINIject
April 30th 2025

iSTAR Medical announces positive 5-year data from STAR-GLOBAL trial for MINIject

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

BVI Medical receives 510(k) FDA clearance for glaucoma surgical system
April 17th 2025

BVI Medical receives 510(k) FDA clearance for glaucoma surgical system

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma
April 7th 2025

Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma

Avisi Technologies releases 6-month interim results from VITA trial
April 4th 2025

Avisi Technologies releases 6-month interim results from VITA trial

© 2025 MJH Life Sciences

All rights reserved.